Hsu KY, Lin JR, Lin MS, Chen W, Chen YJ, Yan YH
Correspondence: Dr Jr-Rung Lin, jr@mail.cgu.edu.tw
ABSTRACT
Introduction Health-related quality of life (HRQoL) is an important patient-centred outcome in chronic obstructive pulmonary disease (COPD). The aim of the current study is to compare the discriminative capacity of the modified Medical Research Council (mMRC) dyspnoea scale and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric classification of COPD on HRQoL, as well as determine other factors that are simple and determinative of HRQoL.
Methods In this cross-sectional observational study, a total of 328 patients with COPD were enrolled from the pulmonology outpatient clinic. HRQoL was measured using the St George’s Respiratory Questionnaire (SGRQ) and the World Health Organization Quality of Life-BREF (WHOQOL-BREF). HRQoL scores were compared between the four GOLD stages and the five grades of the mMRC scale. Significant differences were determined using analysis of variance with Scheffe post-hoc test. Multiple linear regression was applied to explore the major determinants of HRQoL and exclude confounding factors.
Results Signi?cant differences were found in many more domains of the two questionnaires between mMRC grades than between GOLD stages. In the multiple linear regression model, the mMRC scale was the only factor that remained determinative of all the domains of SGRQ and WHOQOL-BREF. Patients with chronic productive cough, sleep disorders and frequent exacerbations had poorer HRQoL, as reflected by higher scores in SGRQ or lower scores in WHOQOL-BREF.
Conclusion The mMRC dyspnoea scale is a concise and practical tool to assess the HRQoL of patients with COPD in daily clinical practice.
Singapore Med J 2013; 54(6): 321-327; http://dx.doi.org/10.11622/smedj.2013125
REFERENCES
1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2010). Available at: http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf. Accessed: August 31, 2011. | ||||
2. Marin JM, Cote CG, Diaz O, et al. Prognostic assessment in COPD: Health related quality of life and the BODE index. Respir Med 2011; 105:916-21. http://dx.doi.org/10.1016/j.rmed.2011.01.007 |
||||
3. Jones PW, Brusselle G, Dal Negro RW, et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med 2011; 105:57-66. http://dx.doi.org/10.1016/j.rmed.2010.09.004 |
||||
4. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-89. http://dx.doi.org/10.1056/NEJMoa063070 |
||||
5. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543-54. http://dx.doi.org/10.1056/NEJMoa0805800 |
||||
6. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059-73. http://dx.doi.org/10.1056/NEJMoa030287 |
||||
7. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122:823-32. http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00003 |
||||
8. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:680-5. http://dx.doi.org/10.1164/rccm.2112043 |
||||
9. Fan VS, Curtis JR, Tu SP, McDonell MB, Fihn SD. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest 2002; 122:429-36. http://dx.doi.org/10.1378/chest.122.2.429 |
||||
10. Engstrom CP, Persson LO, Larsson S, Sullivan M. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J 2001; 18:69-76. http://dx.doi.org/10.1183/09031936.01.00044901 |
||||
11. Antonelli-Incalzi R, Imperiale C, Bellia V, et al. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 2003; 22:444-9. http://dx.doi.org/10.1183/09031936.03.00101203 |
||||
12. Hajiro T,Nishimura K, Tsukino M, Ikeda A, Oga T, Izumi T. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest 1999; 116:1632-7. http://dx.doi.org/10.1378/chest.116.6.1632 |
||||
13. Medinas Amoros M, Mas-Tous C, Renom-Sotorra F, et al. Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index. Chron Respir Dis 2009; 6:75-80. http://dx.doi.org/10.1177/1479972308101551 |
||||
14. Mahler DA, Wells CK. Evaluation of clinical methodsfor rating dyspnea. Chest 1988; 93:580-6. http://dx.doi.org/10.1378/chest.93.3.580 |
||||
15. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:581-6. http://dx.doi.org/10.1136/thx.54.7.581 |
||||
16. Oga T, Nishimura K, Tsukino M, et al. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med 2007; 101:146-53. http://dx.doi.org/10.1016/j.rmed.2006.04.001 |
||||
17. Mannino DM, ThornD, SwensenA,Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32:962-9. http://dx.doi.org/10.1183/09031936.00012408 |
||||
18. Nizet TA, van den Elshout FJ, Heijdra YF, et al. Survival of chronic hypercapnic COPD patients is predicted by smoking habits, comorbidity,and hypoxemia. Chest 2005; 127:1904-10. http://dx.doi.org/10.1378/chest.127.6.1904 |
||||
19. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182:325-31. http://dx.doi.org/10.1164/rccm.200912-1869OC |
||||
20.Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319-38. http://dx.doi.org/10.1183/09031936.05.00034805 |
||||
21. Berglund E,BirathG,Bjure J, et al. Spirometric studies in normal subjects. I. Forced expirograms in subjects between 7 and 70 years of age. Acta Med Scand 1963; 173:185-92. http://dx.doi.org/10.1111/j.0954-6820.1963.tb16520.x |
||||
22. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-7. http://dx.doi.org/10.1164/ajrccm/145.6.1321 |
||||
23. Wang KY, Chiang CH, Maa SH, Shau WY, Tarn YH. Psychometric assessment of the Chinese language version of the St. George's Respiratory Questionnaire in Taiwanese patients with bronchial asthma. J Formos Med Assoc 2001; 100:455-60. | ||||
24. The WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med. 1998; 46:1569-85. | ||||
25. Yao G, Chung CW, Yu CF, Wang JD. Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version. J Formos Med Assoc 2002;101:342-51. | ||||
26. Agusti A. Thomas a. Nefflecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc 2006; 3:478-81. http://dx.doi.org/10.1513/pats.200603-058MS |
||||
27. Papaioannou AI, Loukides S, Gourgoulianis KI, Kostikas K. Global assessment of the COPD patient: time to look beyond FEV1? Respir Med 2009; 103:650-60. http://dx.doi.org/10.1016/j.rmed.2009.01.001 |
||||
28. Jenkins C, Rodriguez-Roisin R. Quality of life, stage severity and COPD. Eur Respir J 2009; 33:953-5. http://dx.doi.org/10.1183/09031936.00019009 |
||||
29. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2:257-66. http://dx.doi.org/10.1136/bmj.2.5147.257 |
||||
30. Jones R, Ostrem A. Optimising pharmacological maintenance treatment for COPD in primary care. Prim Care Respir J 2011; 20:33-45. http://dx.doi.org/10.4104/pcrj.2010.00069 |
||||
31. Bridevaux PO, Gerbase MW, Probst-Hensch NM, et al. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008; 63:768-74. http://dx.doi.org/10.1136/thx.2007.093724 |
||||
32. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-22. http://dx.doi.org/10.1164/ajrccm.157.5.9709032 |
||||
33. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23:698-702. http://dx.doi.org/10.1183/09031936.04.00121404 |
||||
34. Rutgers SR, ten Hacken NH, Koeter GH, Postma DS. Borg scores before and after challenge with adenosine 5'-monophosphate and methacholine in subjects with COPD and asthma. Eur Respir J 2000; 16:486-90. http://dx.doi.org/10.1034/j.1399-3003.2000.016003486.x |
||||
35. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009; 180:1189-95. http://dx.doi.org/10.1164/rccm.200902-0271OC |
||||
36. Annual report of tobacco, alcohol consumption investigation in Taiwan area. Taipei, Taiwan: Bureau of Tobacco and Alcohol Monopoly, Taiwan Provincial Government, 1993. |